Vasculitis and giant cell arteritis
Research activity includes giant cell arteritis with attention to disease control in patients in clinical remission, relapse prevention, and treatment strategies built around glucocorticoid-sparing care. The therapeutic focus extends to inflammatory pathways relevant to large-vessel vasculitis and sustained suppression of disease activity.
- Giant cell arteritis
- Relapse prevention
- Inflammatory disease control
The sponsor’s work in this area reflects interest in managing chronic immune-mediated vascular inflammation and improving long-term symptom stability.
Lipid metabolism and atherosclerotic cardiovascular disease
Clinical research covers hypercholesterolemia and LDL cholesterol lowering in the setting of atherosclerotic cardiovascular disease. The trials examine non-statin lipid management approaches alongside standard background therapy, with a clear emphasis on cardiovascular risk reduction.
- Hypercholesterolemia
- LDL-C reduction
- Atherosclerotic cardiovascular disease
This area highlights sustained involvement in cardiometabolic medicine and the treatment of persistent lipid disorders.
Myeloproliferative neoplasms and polycythemia vera
Another research focus is polycythemia vera, particularly the identification of hydroxyurea resistance and intolerance in patients receiving routine treatment. The sponsor is also engaged with predictive risk assessment in this myeloproliferative neoplasm, supporting more precise management of hematologic disease.
- Polycythemia vera
- Hydroxyurea resistance
- Hematology
These studies place emphasis on treatment responsiveness and disease characterization in chronic blood disorders.
